Huntington's disease: pathogenesis to animal models

Puneet Kumar1, Harikesh Kalonia, Anil Kumar

  • 1Pharmacology Division, University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Study, Panjab University, Chandigarh-160014, India.

Insights

Huntington's disease (HD) is a genetic disorder causing neurodegeneration due to a mutated huntingtin gene. Research explores its complex pathophysiology and potential therapeutic targets, including oxidative stress and mitochondrial dysfunction.

Area of Science:

  • Neuroscience
  • Genetics
  • Pathophysiology

Background:

  • Huntington's disease (HD) is an inherited neurodegenerative disorder characterized by cognitive and motor deficits.
  • It results from an expanded CAG repeat in the huntingtin gene, leading to progressive striatal and cortical neurodegeneration.
  • The precise pathogenic mechanisms of mutant huntingtin remain incompletely understood, driving ongoing research.

Purpose of the Study:

  • To review the pathophysiology and contributing cascades in Huntington's disease.
  • To identify potential drug targets for therapeutic intervention.
  • To examine the role and limitations of animal models in HD research.

Main Methods:

  • Literature review of Huntington's disease pathophysiology.
  • Analysis of proposed pathogenic mechanisms including excitotoxicity, apoptosis, and oxidative stress.
  • Evaluation of various therapeutic targets and animal models.

Main Results:

  • Oxidative stress and mitochondrial dysfunction are implicated in HD pathogenesis.
  • Multiple neurotransmitter systems (dopaminergic, GABAergic, glutamatergic) and pathways are potential drug targets.
  • Animal models are crucial for studying HD mechanisms and testing therapies, each with unique strengths and weaknesses.

Conclusions:

  • Understanding the complex pathophysiology of HD is crucial for developing effective treatments.
  • Targeting pathways like oxidative stress, mitochondrial function, and neurotransmitter systems offers potential therapeutic avenues.
  • Continued research using diverse animal models is essential for unraveling HD mechanisms and identifying novel drug targets.

Related Concept Videos

Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...